CNS disorder – Talk Bio

Actionable Insights Powered by AI

Relmada Acquires Promising Tourette’s Syndrome Drug Candidate from Asarina Pharma

2 months ago talkbio0Tagged Acquisition, Asarina, asset, CNS disorder, Neurosteroids, Pharma, Phase 2b, Pregnanolone, (3beta, 5alpha)-isomer, Relmada, Tourette 's syndrome

Relmada Therapeutics, Asarina Pharma, Sepranolone, Tourette’s syndrome, neurosteroid, Phase 2b, asset acquisition, CNS disorders

Relmada Therapeutics Explores Strategic Alternatives Following Discontinuation of Two Phase 3 Trials

4 months ago talkbio0Tagged CNS disorder, Metabolic Diseases, Phase 3 trials, REL-1017, Relmada, strategic alternatives

Relmada Therapeutics, Phase 3 trials, Strategic alternatives, REL-1017, REL-P11, Central nervous system diseases, Metabolic disorders

Axonis Secures $115 Million to Develop Novel Treatment for Drug-Resistant Pain and Epilepsy

6 months ago talkbio0Tagged Axonis, CNS disorder, drug-resistant pain, Epilepsy, GABA-related, Psychological inhibition, SLC12A5 gene

Axonis Therapeutics, drug-resistant pain, epilepsy, CNS disorders, KCC2, GABA-related inhibition, series A funding

AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics

6 months ago talkbio0Tagged AbbVie, ALIA-1758, Aliada, Alzheimer 's disease, anti-amyloid, asset, Blood - brain barrier anatomy, CNS disorder, pharmaceutical acquisition, Study models, Technology

AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition